In addition, clinical trial data demonstrate that VP1-based vaccines can stimulate other immunologic markers potentially associated with the protection of norovirus disease and infection, such as serum immunoglobulin G (IgG), serum immunoglobulin A (IgA), fecal IgA, salivary IgA, and norovirus-specific memory IgG B-cells23,25,26. The gene discussed is CD79A; the disease is infection.